Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Delivery: Parenteral Route01:29

Drug Delivery: Parenteral Route

1.5K
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phenotype, Severity, and Therapy of Patients With LRP4 Antibody-Associated Myasthenia Gravis in the German Myasthenia Gravis Registry.

Neurology·2026
Same author

Proinflammatory Epstein-Barr Virus Antibody Functions Track with Disease Activity in Multiple Sclerosis.

Annals of neurology·2026
Same author

Rogue clones: When MS autoimmunity goes viral.

Science immunology·2026
Same author

Meningococcal prophylaxis in neurological diseases treated with complement inhibitors: an expert consensus for Germany, Austria, and Switzerland.

Therapeutic advances in neurological disorders·2026
Same author

Multicentric prognostic observational study on biomarker profile in immunotherapy-naïve patients with highly active generalized myasthenia gravis (PROGNO-MG): a study protocol.

Neurological research and practice·2026
Same author

Efficacy and Safety of Vemircopan in Generalized Myasthenia Gravis: A Randomized Clinical Trial.

JAMA neurology·2026

Related Experiment Video

Updated: Jan 14, 2026

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
10:35

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

8.6K

Intravenous immunoglobulin use in neurology.

Christian W Keller1, Marinos C Dalakas2, Jan D Lünemann3

  • 1Department of Neurology and Neurophysiology, Medical Center, University of Freiburg, Freiburg, Germany.

Handbook of Clinical Neurology
|January 12, 2026
PubMed
Summary

Intravenous immunoglobulin (IVIg) effectively treats autoimmune neurologic disorders like Guillain-Barré syndrome. Research explores its use and alternatives due to increasing demand and supply shortages.

Keywords:
Immunomodulation by IVIgInitiating and stopping IVIgIntravenous immunoglobulinNeurologic disorders

More Related Videos

Intravenous Injections in Neonatal Mice
05:17

Intravenous Injections in Neonatal Mice

Published on: November 11, 2014

60.9K
Intracerebroventricular and Intravascular Injection of Viral Particles and Fluorescent Microbeads into the Neonatal Brain
05:51

Intracerebroventricular and Intravascular Injection of Viral Particles and Fluorescent Microbeads into the Neonatal Brain

Published on: July 24, 2016

20.4K

Related Experiment Videos

Last Updated: Jan 14, 2026

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
10:35

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

8.6K
Intravenous Injections in Neonatal Mice
05:17

Intravenous Injections in Neonatal Mice

Published on: November 11, 2014

60.9K
Intracerebroventricular and Intravascular Injection of Viral Particles and Fluorescent Microbeads into the Neonatal Brain
05:51

Intracerebroventricular and Intravascular Injection of Viral Particles and Fluorescent Microbeads into the Neonatal Brain

Published on: July 24, 2016

20.4K

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Intravenous immunoglobulin (IVIg), derived from pooled plasma of healthy donors, has significantly advanced autoimmune neurologic disorder treatment over 30 years.
  • Randomized controlled trials support IVIg's efficacy in Guillain-Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy (MMN), and dermatomyositis.
  • IVIg also shows effectiveness in myasthenia gravis exacerbations, stiff-person syndrome, and autoimmune encephalitides.

Purpose of the Study:

  • To review the clinical applications of IVIg in various neurologic diseases.
  • To discuss the therapeutic value of subcutaneous immunoglobulin (SCIg) as an alternative or adjunct to IVIg.
  • To address practical considerations for IVIg therapy, including dosing, administration schedules, and treatment cessation.

Main Methods:

  • Review of randomized controlled trials and clinical studies evaluating IVIg and SCIg in neurologic disorders.
  • Analysis of treatment outcomes for specific autoimmune neuropathies and encephalitides.
  • Discussion of current challenges, including IVIg supply shortages and the exploration of recombinant alternatives.

Main Results:

  • IVIg is an approved and effective treatment for several autoimmune neurologic conditions.
  • Both IVIg and SCIg demonstrate efficacy as maintenance therapy, particularly in CIDP and MMN.
  • Growing demand for IVIg necessitates exploring alternative strategies, including recombinant products.

Conclusions:

  • IVIg remains a cornerstone therapy for numerous autoimmune neurologic disorders.
  • SCIg offers a viable alternative for maintenance therapy in specific conditions.
  • Addressing IVIg supply limitations and investigating novel therapeutic approaches are critical for future patient care.